BEIGENE LTD-ADR (BGNE)       144.94  +7.8 (+5.69%)

144.94  +7.8 (+5.69%)

US07725L1026 - ADR - After market: 145 +0.06 (+0.04%)

BEIGENE LTD-ADR144.94

NASDAQ:BGNE (10/4/2022, 7:14:42 PM)+7.8 (+5.69%)

After market: 145 +0.06 (+0.04%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-04 2022-08-04/amc Earnings (Next) 11-02 2022-11-02
Ins Owners 30.21% Inst Owners 51.97%
Market Cap 15.02B Shares 103.63M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 85.71
IPO 02-03 2016-02-03

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BGNE Daily chart

Company Profile

BeiGene, Ltd. (BeiGene) is a global biotechnology company. The Company is focused on discovering, developing, manufacturing, and commercializing medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers, tislelizumab; an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers, and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company also has other products in its clinical stage, including BGB-283, BGB-3245, BGB-11417, BGB-A445, BGB-A425, BGB-15025, BGB-A333, BGB-A1217, and BGB-10188. The Company operates offices in 30 countries on five continents, namely the United States, China, Europe, and Australia.

Company Info

BEIGENE LTD-ADR

C/O Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay

George Town BEIJING KY1-1108

P: 13459494123.0

CEO: John V. Oyler

Employees: 8033

Website: http://www.beigene.com/

BGNE Twits

Here you can normally see the latest stock twits on BGNE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example